PATENT CLAIM ANALYSIS

Application Number: 16168242
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-07
Patent Classification: ["514", "017500"]

Abstract:
The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine site partial agonist.

Claim (Index 2):
The method of  claim 1 , wherein about 1 day after administration, the patient has substantial improvement in one or more autism symptoms.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14050641', '14580803', '15328341', '14764419', '15653738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7910956300240196
- 35 USC 102 Novelty (BERT): 0.5373925444030985
- Combined Prediction Score: 0.7657253214619275
- Mean Citation Score: 318.149788
- Max Citation Score: 376.27896
- Similarity Product: 241.266325941124

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test